Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Hope S Rugo Aditya Bardia Frederic Marmé Javier Cortes Peter SchmidDelphine LoiratOlivier Trédan Eva Ciruelos GilFlorence DalencPatricia Gómez PardoKomal L JhaveriRosemary DelaneyOlivia FuLanjia LinWendy VerretSara M Tolaney

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
tyrosine kinase
advanced non small cell lung cancer
endothelial cells
induced pluripotent stem cells
locally advanced
pluripotent stem cells
squamous cell carcinoma
breast cancer risk